However, the sFlt-1/PlGF ratio still demonstrated a comparable predictive performance between cohorts in terms of the NPV for ruling out preeclampsia within 1 week (Japanese cohort: 100% [95% CI, 97.5–100.0]; PROGNOSIS validation cohort: 99.3% [95% CI, 97.9–99.9]), and the PPV for ruling in preeclampsia within 4 weeks (32.4% versus 36.7%) and the area under the ROC curve values for the combined endpoint were similar for the PROGNOSIS Asia Japan cohort versus PROGNOSIS (1 week: 94.2% versus 88.3%; 4 weeks: 85.9% versus 86.4%), despite some differences between cohorts. Here, PGF is linked to preeclampsia.